Please login to the form below

Not currently logged in
Email:
Password:

Dr Martin Rothman joins Sofinnova Partners

He becomes the firm’s venture partner

RothmanLife Science-focused European venture capital firm, Sofinnova Partners, has appointed Dr Martin Rothman as venture partner.

Rothman brings 40 years of experience along with an international network in the medical field to Sofinnova Partners. There, he will focus on helping the team identify and evaluate “promising” medical device companies.

His new position at the firm will also see him take on a mentor role, as he will guide entrepreneurs and physicians launching clinical innovations.

Rothman said: “I am thrilled to join Sofinnova Partners’ team as venture partner.

“We share a common vision of entrepreneurship and a passion for bringing innovative therapies to patients and the medical community.”

Until recently, Rothman was vice president of medical affairs for coronary, structural heart and renal denervation for Medtronic, where he held that position since 2010.

Commenting on the appointment, Antoine Papiernik, managing partner and chairman of Sofinnova Partners, said: “Martin is an exceptional physician and repeat entrepreneur.

“His experience ideally complements our team and represents a key asset for Sofinnova Partners at a time when our activity is growing.”

22nd May 2018

From: Sales

Share

Tags

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Dovetail

About Dovetail We’re award-winning specialists in healthcare collaboration that makes patients’ lives better. Combining expertise with a passion for collaboration,...

Latest intelligence

Working together against COVID-19
Analysing social media conversations to see what HCPs are saying online about the global pandemic...
Vicky Bramham, Managing Director at OPEN Health PR shares tips on media relations during COVID-19
Vicky speaks with freelance health journalist Jacqui Thornton who gives her expert view on how best to approach media relations during this unprecedented time....
Are biobetters a market access opportunity?
Biobetters are biologics that have been improved compared to the marketed originator, for example in efficacy, safety, tolerability or dosing regimen....

Infographics